Skip to main content
Saniona logo

Saniona — Investor Relations & Filings

Ticker · SANION ISIN · SE0005794617 LEI · 549300XO4L9XNOCFCZ84 ST Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2020-05-06 Declaration of Voting R…
Country SE Sweden
Listing ST SANION

About Saniona

http://saniona.com

Saniona is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurological disorders, with a primary emphasis on epilepsy. The company is a leader in the field of ion channel modulation, leveraging its expertise and a proprietary drug discovery engine to create new medicines. Saniona has developed an extensive library of over 20,000 proprietary molecules designed to target various ion channels. Its pipeline includes multiple potential new medicines advancing through clinical trials, with the goal of addressing unmet medical needs for patients with central nervous system diseases.

Recent filings

Filing Released Lang Actions
KOMMUNIKÉ FRÅN SANIONA AB:S ÅRSSTÄMMA DEN 6 MAJ 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release titled 'KOMMUNIKÉ FRÅN SANIONA AB:S ÅRSSTÄMMA' (Communiqué from Saniona AB's Annual General Meeting). It details the resolutions passed during the AGM held on May 6, 2020, including the approval of financial statements, discharge of board members, election of the board and auditors, and authorization for share issues. This is a standard report of voting results and decisions made at an Annual General Meeting, which falls under the 'Declaration of Voting Results & Voting Rights Announcements' category.
2020-05-06 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT FÖR SANIONA AB (PUBL)' which translates to 'Interim Report for Saniona AB (Publ)' and covers the period January to March 2020. It contains detailed financial data such as net revenue, EBIT, earnings per share, cash flow, balance sheet items, and operational highlights for the quarter. It also includes management commentary, business updates, and strategic progress. The length is substantial (15,000 characters) and it contains actual financial statements and analysis for a period shorter than a full fiscal year (quarterly). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-05-06 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT FOR SANIONA AB (PUBL)' and covers the period 'January - March 2020'. It contains comprehensive financial statements, including income statements, cash flow data, and balance sheet information, as well as management commentary and business highlights. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2020
2020-05-06 English
Saniona appoints Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Medical Officer (Dr. Rudolf Baumgartner) at Saniona. This falls under the category of management changes, which is explicitly defined as 'Board/Management Information' (MANG).
2020-04-27 English
Saniona utser Rudolf Baumgartner till Chief Medical Officer och Head of Clinical Development
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Medical Officer (Rudolf Baumgartner) at Saniona. This falls under the category of management changes, which is explicitly defined as 'Board/Management Information' (MANG).
2020-04-27 Swedish
Saniona meddelar positiva topline-resultat i Fas 2-studien av Tesomet vid hypotalamisk fetma
Regulatory Filings Classification · 95% confidence The document is a press release from Saniona announcing positive topline results from a Phase 2 clinical trial for their drug candidate, Tesomet. It details clinical trial outcomes, safety data, and management commentary. It does not fit into financial reporting categories like 10-K or IR, nor is it a regulatory filing for a specific corporate action like a dividend or share issue. As it is a general regulatory announcement regarding clinical trial progress, it falls under the 'Regulatory Filings' (RNS) category.
2020-04-22 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.